MétaCan
Menu
Back to cohort

PTU-009 Long-term effects of obeticholic acid in patients with primary biliary cholangitis on inflammatory markers

2019· article· en· W3021996884 on OpenAlexaff
Gideon M. Hirschfield, Frederik Nevens, Mitchell L. Shiffman, Joost P H Drenth, Christopher L. Bowlus, Vı́ctor Vargas, Pietro Andreoné, Stephen Ryder, A. Sender Liberman, Elizabeth Smoot Malecha, Leigh MacConell, Michael Trauner

Bibliographic record

Venuenot available
Typearticle
Languageen
FieldMedicine
TopicLiver Diseases and Immunity
Canadian institutionsToronto Liver CentreUniversity of Toronto
Fundersnot available
KeywordsObeticholic acidMedicineInternal medicineGastroenterologyPrimary biliary cirrhosisPlaceboUrsodeoxycholic acidCholestasisFarnesoid X receptorBile acidCirrhosisAgonistReceptorPathology

Abstract

fetched live from OpenAlex

Introduction Obeticholic Acid (OCA) is a potent and selective farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC). PBC is a chronic liver disease characterized by the immune mediated destruction of bile ducts resulting in cholestasis, cirrhosis and liver failure. The POISE study was a randomized, placebo-controlled phase 3 study investigating daily OCA 5–10 mg in PBC patients with an ongoing open label extension (OLE). The purpose of this analysis was to assess the long-term effects of OCA on key markers of liver damage and inflammation. Methods Patients enrolled in the double-blind phase had an inadequate response to UDCA or were intolerant of UDCA. Patients were randomized to placebo, OCA 5–10 mg, or OCA 10 mg. Upon completion of the 12-month double-blind phase, 198 patients enrolled in the OLE and received OCA. For this analysis, patients were pooled and assessed from the time of first dose of OCA. Data are shown through 48 months of OCA exposure, for patients randomized to placebo in the double-blind phase, only 36 months of data are included. Results At baseline (N=198), patients were 92% female, mean age was 55 years, PBC disease duration was 9 years, and 93% received UDCA (mean dose: 16 mg/kg/day). As observed in the table, there were sustained and significant reductions in immunoglobulins (Ig) A, G and M throughout 48 months of OCA treatment. In addition, significant reductions were observed in tumor necrosis factor (TNF)-α, c-reactive protein (CRP), and cleaved cytokeratin (CK)-18 throughout the duration of the OLE. No clinically meaningful changes were observed with transforming growth factor (TGF)-β and interleukin (IL)-12, both remained within the normal range. Conclusions These results demonstrate that OCA has a durable anti-inflammatory effect in patients with PBC as observed by reductions on key markers of apoptosis (TNF-α and CK-18) and inflammation (CRP). Furthermore, a sustained reduction is observed in IgM, which is classically elevated in PBC patients. The clinical significance of OCA mediated reductions in IgA and IgG continues to remain unknown.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.003
GPT teacher head0.192
Teacher spread0.189 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same topicLiver Diseases and ImmunityFrench-language works237,207